Malignant Mesothelioma: Clinical, Pathological and Radiological Findings

被引:1
|
作者
Sapmaz, Feride [1 ]
Lakadamyali, Hseyin [2 ]
Katrancioglu, Ozgur [3 ]
Yildirim, Yesim [4 ]
Dongel, Isa [3 ]
机构
[1] Baskent Univ Alanya Arastirma & Uygulama Merkezi, Gogus Cerrahisi AD, TR-07400 Alanya, Antalya, Turkey
[2] Baskent Univ Alanya Arastirma & Uygulama Merkezi, Gogus Hastaliklari AD, Alanya, Turkey
[3] Gogus Cerrahisi Klin, Sivas Numune Hastanesi, Sivas, Turkey
[4] Tibbi Onkoloji Bolumu, Acibadem Kozyatagi Hastanesi, Istanbul, Turkey
关键词
Malignant Pleural Mesothelioma; Pathology; Radiology; Mortality;
D O I
10.4328/JCAM.544
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: Malignant pleural mesothelioma is a tumor of locally invasive character and of fatal course, frequently arising following asbest exposure. In the present study we attempted to retrospectively evaluate the clinical, pathological, and radiological findings of 27 cases diagnosed with MPM. Material and Method: 27 cases diagnosed with MPM in our medical facility have been included into the study, 14 females, and 13 males. Of the cases, 4 have been diagnosed based on transthoracic pleural biopsy, and 23 - using surgical methods (VYTC, thoracotomy). Result: Radiological evaluation revealed pleural thickening in 23 (85.2%), pleural effusion in 20 (74.1%), volume loss in 15 (55.6%), pleural nodulation in 14 (51.9%), mediastinal shift in 4 (14.8%), pneumothorax in 1 (3.7%), and hydropneumothorax in 1 (3.7%) of the cases, respectively. Histopathological examination failed to reveal any typing in 17 (63%) of the cases. On the other hand, 5 (18.5%) of the remainder cases were of the epitheloid type, 4 (14.8%) were of the sarcomatoid type, and 1 (3.7%) was of the biphasic MPM type. Mean survival rate of the 3 (11.1%) Stage I cases was 1449 days, of the 6 (22.2%) Stage II cases was 480 days, of the 18 (66.7%) Stage III cases was 214 days. We had no Stage IV cases at the time of diagnosis. A statistically significant difference has been established between the Stage and the mean survival rate of the cases. Discussion: In diagnosing MPM, proper histopathological exam followed by proper radiological staging should be carried out. A multimodality approach comprises the present MPM treatment, but total cure cannot be provided.
引用
收藏
页码:51 / 55
页数:5
相关论文
共 50 条
  • [21] Clinical, radiological, pathological and prognostic aspects of intraventricular oligodendroglioma: comparison with central neurocytoma
    Xiang Xiao
    Jun Zhou
    Jun Wang
    Lei Yang
    Chunhong Wang
    Yikai Xu
    Yuankui Wu
    Journal of Neuro-Oncology, 2017, 135 : 57 - 65
  • [22] Clinical, radiological, pathological and prognostic aspects of intraventricular oligodendroglioma: comparison with central neurocytoma
    Xiao, Xiang
    Zhou, Jun
    Wang, Jun
    Yang, Lei
    Wang, Chunhong
    Xu, Yikai
    Wu, Yuankui
    JOURNAL OF NEURO-ONCOLOGY, 2017, 135 (01) : 57 - 65
  • [23] Review on clinical trials of targeted treatments in malignant mesothelioma
    Jan Nyrop Jakobsen
    Jens Benn Sørensen
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1 - 15
  • [24] Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma
    R. Berardi
    M. Caramanti
    I. Fiordoliva
    F. Morgese
    A. Savini
    S. Rinaldi
    M. Torniai
    M. Tiberi
    C. Ferrini
    M. Castagnani
    F. Rovinelli
    A. Onofri
    S. Cascinu
    Supportive Care in Cancer, 2015, 23 : 621 - 626
  • [25] Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma
    Mencoboni, Manlio
    Filiberti, Rosa A.
    Taveggia, Paola
    Grosso, Federica
    Pasello, Giulia
    Del Corso, Lisette
    Muzio, Alberto
    Polo, Valentina
    Zucali, Paolo
    Ceresoli, Giovanni L.
    Parra, Hector J. Soto
    Auriati, Laura
    Simonassi, Claudio
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (06) : 364 - 369
  • [26] Clinical and biologic prognostic factors in malignant pleural mesothelioma
    Ambrogi, Vincenzo
    Mineo, Tommaso Claudio
    THORACIC CANCER, 2012, 3 (04) : 289 - 302
  • [27] Review on clinical trials of targeted treatments in malignant mesothelioma
    Jakobsen, Jan Nyrop
    Sorensen, Jens Benn
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (01) : 1 - 15
  • [28] Clinical Impact of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
    Vincenzo Ambrogi
    Alfonso Baldi
    Orazio Schillaci
    Tommaso Claudio Mineo
    Annals of Surgical Oncology, 2012, 19 : 1692 - 1699
  • [29] Clinical and Pathological Features Are Still the Best Determinants of Prognosis in Mesothelioma
    Miller, Andrew C.
    Hassan, Raffit
    ONCOLOGY-NEW YORK, 2012, 26 (12): : 1176 - 1180
  • [30] Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma
    Marulli, Giuseppe
    Di Chiara, Francesco
    Braccioni, Fausto
    Perissinotto, Egle
    Pasello, Giulia
    Favaretto, Adolfo G.
    Breda, Cristiano
    Rea, Federico
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2013, 44 (01) : 104 - 110